ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0210

Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0527

Risk Factors for Leukopenia in Asian Patients with Rheumatoid Arthritis Undergoing Tocilizumab

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0453

Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0719

Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0048

Role of the Chemokine CCL22 in Rheumatoid Arthritis Development

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0177

Rural-urban Disparities in the Myocardial Infarction Hospitalizations in People with Systemic Lupus Erythematosus in the US

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0737

Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0291

Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0138

SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0515

Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0644

Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0469

SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0107

Screening for Non-criteria Antiphospholipid Autoantibodies in Patients Younger Than 50 Years Old Admitted for Venous Thromboembolism: A Cross-sectional Study

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0195

Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0604

Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024

SpA Including PsA – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].